Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00357760 · ClinicalTrials.gov registry record · Phase 2
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT00357760: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00357760 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 94 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00357760, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well ziv-aflibercept (VEGF Trap) works in treating patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) or is unable to be removed with surgery (unresectable). Ziv-aflibercept may stop the growth of kidney cancer by blocking blood flow to the tumor.
Interventions
- BIOLOGICAL VEGF Trap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2007-12 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00357760
The ClinicalTrials.gov registry entry for NCT00357760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VEGF Trap is the first listed.
NCT00357760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00357760 about?
NCT00357760 is a clinical study titled "Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer". This randomized phase II trial studies how well ziv-aflibercept (VEGF Trap) works in treating patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) or is unable to be removed with surgery (unresectable). Ziv-aflibercept may stop the growth of kidn...
What is the current status of trial NCT00357760?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2007-12. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00357760?
The interventions under investigation include: VEGF Trap (BIOLOGICAL).
Who is sponsoring clinical trial NCT00357760?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.